Safety and clinical benefits of palliative surgery for metastatic gastrointestinal stromal tumor

doi:10.3969/j.issn.1009-976X.2015.06.001

Abstract

Abstract:

【Abstract】〓Objective〓To study the safety and clinical benefits of the advanced gastrointestinal stromal tumor (GIST) patients who underwent palliative surgery after tyrosine kinase inhibitors (TKIs) treatment. Methods〓We evaluated the safety and outcomes in a single institution series of advanced GIST patients from January 2002 to December 2008. Patients were categorized into two groups based on whether underwent surgical resection. Results〓156 patients had been recruited in this study, including 87 patients underwent surgical resection and 69 patients kept on TKIs treatment. There was no difference in the clinicopathological features between two groups, and 4 patients had surgical complications. Median follow-up was 23.7 months. The OS and PFS of the patients in surgical group were longer than the non-surgical group, PFS: 46.1 months vs 33.8 months (P<0.01), OS: 54.8 months vs 40.4 months and the 2 years progression-free disease rate was 89.7% vs 85.5%,P<0.01,respectively. Conclusion〓Patients with advanced GISTs have prolonged overall survival after debulking procedures. Surgery for patients with metastatic GIST who have responsive disease after TKIs treatment should be considered.

Key words: Gastrointestinal stromal tumor, Safety, Prognosis, Surgery

摘要：

【摘要】目的研究晚期胃肠间质瘤患者经过了酪氨酸激酶抑制剂治疗后接受姑息手术的安全性和对预后的影响。方法〓回顾性研究选取中山大学肿瘤防治中心2002年1月~2008年12月间治疗晚期胃肠间质瘤患者,分成两组,手术组和未手术组。两组分别比较临床病理因素和预后的差异。结果〓总共有156例患者入组本研究,其中87例患者接受了姑息手术的,69例患者未接受手术治疗,两组临床病理因素并无明显差异。接受手术的患者中,共有4例(4.6%)患者出现了手术相关并发症,无手术相关死亡。中位随访时间23.7个月,手术组患者其总体生存时间(Overall Survival, OS)和无进展生存时间(Progression-free Survival, PFS)均明显长于未手术组患者,中位PFS分别为46.1个月(手术组)和33.8个月(未手术组),两组2年无疾病生存率分别为:89.7% vs 85.5%, P<0.01,结果具有显著的统计学差异。类似的,中位OS在两组分别为54.8个月(手术组)和40.4个月(未手术组),P<0.01,结果具有统计学意义。亚组分析发现,不论是原发于胃或非胃,原发突变位于c-KIT外显子11,手术组预后均好于非手术组。结论〓晚期胃肠间质瘤患者酪氨酸激酶抑制剂后反应有效的患者,手术安全性良好,接受手术可改善患者预后。

关键词: 手术, 预后, 安全性, 胃肠间质瘤

CLC Number:

R656
R735

Qiu Haibo,Guo Jing,Liu Xuechao,Seeruttum Sharvesh Raj,Nie Runcong,Wu Ting,Sun Xiaowei,Zhou Zhiwei. Safety and clinical benefits of palliative surgery for metastatic gastrointestinal stromal tumor[J]. Lingnan Modern Clinics in Surgery, 2015, 15(06): 647-652.

邱海波国婧刘学超沙维斯聂润聪吴婷孙晓卫周志伟. 晚期胃肠间质瘤姑息手术的安全性与临床获益分析[J]. 岭南现代临床外科, 2015, 15(06): 647-652.

References

参考文献
1. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002;33:459-65.
2. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006;23:70-83.
3. Nakahara M, Isozaki K, Hirota S, et al. A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors. Gastroenterology 1998;115:1090-5.
4. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-10.
5. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80.
6. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006;130:1466-78.
7. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-8.
8. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
9. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-38.
10. Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:295-302.
11. Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008;26:5360-7.
12. Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008;26:5352-9.
13. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
14. Zhang J, Fujimoto J, Wedge DC, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 2014;346:256-9.
15. Raut CP, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006;24:2325-31.
16. DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF, Antonescu CR. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007;245:347-52.
17. Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008;359:453-62.
18. Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999;340:908-14.

[1]	OU Xin-yu, LU Yi-wen, LIU Zhi-han, SU Shi-cheng. Application of intra-operative navigation in endoscopic breast conserving surgery：a case report [J]. Lingnan Modern Clinics In Surgery, 2022, 22(1): 1-5.
[2]	HE Chong, ZHOU Shu-rui, LI Ya-qing, CHEN Shao-jie, LIAN Guo-da, CHEN Shang-xiang, HUANG Kai-hong. Screening of ferroptosis-related genes and construction of prognostic prediction model in pancreatic cancer [J]. Lingnan Modern Clinics In Surgery, 2022, 22(1): 14-23.
[3]	HUANG Yong-feng, OU Rong-tong, PAN Ying-song. Comparison of the effect of MIS-TLIF and TLIF surgery in the treatment of single-segment lumbar spinal stenosis [J]. Lingnan Modern Clinics In Surgery, 2022, 22(1): 71-74.
[4]	CHEN Hai-ming, XU Ling-ling, LI Jian-guang, LUO Hui-ming. Application of enhanced recovery after surgery（ERAS）in the treatment of annular mixed hemorrhoids during perioperative period [J]. Lingnan Modern Clinics In Surgery, 2022, 22(1): 75-78.
[5]	HUANG Sai-lin, XU Shao-qiang, FAN Yan-li, LI Lian, ZHENG Tao, SHI Hong-zhi. Retrospective analysis of pathogenic bacteria results of hospital-acquired infection in neurosurgery inpatients [J]. Lingnan Modern Clinics In Surgery, 2022, 22(1): 84-88.
[6]	Liu Wei. Five-year follow-up analysis of clinical efficacy of radiotherapy alone and radiochemotherapy in malignant glioma [J]. Lingnan Modern Clinics In Surgery, 2022, 22(1): 89-93.
[7]	HE Xu-hui, ZHENG Chao-shun, GUO Yue-yue, ZHANG Long-sheng, XING Ze-hua, LIN ben-dan. Implication of enhanced recovery after surgery （ERAS） in anterior cervical discectomy and fusion surgery [J]. Lingnan Modern Clinics In Surgery, 2022, 22(1): 98-102.
[8]	HU Ming-chao, ZHU Bao-song. Bioinformatics analysis of the diagnostic and prognostic value of the NDC1 gene in colon cancer： a study based on TCGA database [J]. Lingnan Modern Clinics In Surgery, 2021, 21(06): 598-602.
[9]	CAO Hong-tao, WANG Xiao-long, CHEN Liang, LIN Bo, TANG Ting-ting, MA Ke-qiang, JI Teng-fei, CAO Tian-sheng, WANG Jian, ZHANG Wen-wei, YANG Jian-rong, LU Zhuo-cai, YOU Tian, HE Qing-qing, HUANG Jin-min, ZHOU Ti-xia. Experience in the treatment of SOX neoadjuvant chemotherapy in advanced gastric cancer [J]. Lingnan Modern Clinics In Surgery, 2021, 21(06): 631-635.
[10]	YANG Jian-min, ZOU Su-wen, LI Min-ying, OU Qiao-yan. Effect of vacuum-assisted excision and open surgery on breastfeeding capability of breast fibroadenoma patients [J]. Lingnan Modern Clinics In Surgery, 2021, 21(06): 636-639.
[11]	CHEN Hai-jun, SUN Zi-cheng, LIU Yan, FAN De-biao, HUANG Zhong-xian, ZHANG Ti. The application study of enhanced recovery after surgery （ERAS） in the laparoscopy combined with choledochoscopy in the treatment of choledocholithiasis [J]. Lingnan Modern Clinics In Surgery, 2021, 21(05): 516-520.
[12]	SHEN Tao, LU Zhu-ming, DUAN Chu-xiao, ZHANG Dong-xi, YE min, LIN Zhi-chao. Lymph node metastasis of simultaneous multiple primary lung cancer [J]. Lingnan Modern Clinics In Surgery, 2021, 21(05): 561-565.
[13]	WANG Dao-du, ZHAO Qi-jiong, ZHOU Zhi-biao, HE Yong-yue. Development of the prognosis signature for hepatocellular carcinoma based on ferroptosis-related genes [J]. Lingnan Modern Clinics In Surgery, 2021, 21(04): 419-424.
[14]	MA Can-ye, YANG Fan, LI Bao-jin. Evidence and treatment of post-thyroidectomy hypocalcemia in patients with history of bariatric operations [J]. Lingnan Modern Clinics In Surgery, 2021, 21(04): 432-436.
[15]	WU Bo-chu, WU Xian-ju, LUO Chun-qiang. Observation of the enhanced recovery after surgery in patients with femoral intertrochanteric fractures [J]. Lingnan Modern Clinics In Surgery, 2021, 21(04): 449-452.